• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Entrada Therapeutics Inc.

    7/1/25 5:03:16 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRDA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001674324
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Entrada Therapeutics, Inc.
    SEC File Number
    001-40969
    Address of Issuer
    ONE DESIGN CENTER PLACE
    SUITE 17-500
    BOSTON
    MASSACHUSETTS
    02210
    Phone
    857-305-1825
    Name of Person for Whose Account the Securities are To Be Sold
    5AM Ventures V, L.P.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    TD Securities (USA) LLC
    1 Vanderbilt Ave
    New York � NY � 10017
    18578132323.663795341707/01/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/28/2017Venture InvestmentEntrada Therapeutics, Inc.Checkbox not checked1857809/28/2017Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    5AM Ventures V, L.P.
    4 Embarcadero Center, Suite 3110
    San Francisco � CA � 94111
    Common06/27/202555735385128.85
    5AM Ventures V, L.P.
    4 Embarcadero Center, Suite 3110
    San Francisco � CA � 94111
    Common06/30/202518578126566.34

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/01/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Andrew J. Schwab

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TRDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRDA

    DatePrice TargetRatingAnalyst
    12/6/2024$29.00Buy
    ROTH MKM
    1/5/2024$22.00Outperform
    Oppenheimer
    4/3/2023$25.00Buy
    H.C. Wainwright
    11/24/2021Outperform
    Evercore ISI Group
    11/23/2021Outperform
    Cowen & Co.
    11/23/2021$29.00Neutral
    Goldman Sachs
    More analyst ratings

    $TRDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parmar Kush sold $866,632 worth of shares (125,000 units at $6.93) (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      7/1/25 8:33:41 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner 5am Ventures V, L.P. sold $866,632 worth of shares (125,000 units at $6.93) (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      7/1/25 8:32:14 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Kim Peter S bought $731,682 worth of shares (50,000 units at $14.63), increasing direct ownership by 74% to 117,412 units (SEC Form 4)

      4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      6/18/25 4:32:46 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Entrada Therapeutics with a new price target

      ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00

      12/6/24 8:19:11 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Entrada Therapeutics with a new price target

      Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00

      1/5/24 8:45:46 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Entrada Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $25.00

      4/3/23 7:39:53 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    SEC Filings

    See more
    • SEC Form 144 filed by Entrada Therapeutics Inc.

      144 - Entrada Therapeutics, Inc. (0001689375) (Subject)

      7/1/25 5:03:16 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Entrada Therapeutics Inc.

      144 - Entrada Therapeutics, Inc. (0001689375) (Subject)

      7/1/25 5:01:40 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Entrada Therapeutics Inc.

      144 - Entrada Therapeutics, Inc. (0001689375) (Subject)

      6/30/25 5:06:37 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Kim Peter S bought $731,682 worth of shares (50,000 units at $14.63), increasing direct ownership by 74% to 117,412 units (SEC Form 4)

      4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      6/18/25 4:32:46 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kim Peter S bought $364,672 worth of shares (25,000 units at $14.59), increasing direct ownership by 37% to 92,412 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      5/16/24 4:33:48 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kim Peter S bought $63,306 worth of shares (4,476 units at $14.14), increasing direct ownership by 7% to 67,412 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      5/10/24 4:35:37 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units ("RSUs") to six newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quart

      6/2/25 4:30:00 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

      – Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. "ELEVATE-45-201 is the most advanced clinical

      5/28/25 7:00:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

      āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

      9/17/24 8:30:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

      BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit

      8/10/23 7:00:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Entrada Therapeutics Inc.

      SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      11/14/24 1:22:40 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Entrada Therapeutics Inc.

      SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      6/26/24 4:54:17 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Entrada Therapeutics Inc. (Amendment)

      SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      2/14/24 4:26:22 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care